Evotec SE
Evotec SE is a life science company that provides drug discovery and development services across small molecules, biologics, cell therapies, and related modalities. It operates through a network of scientific platforms and partnerships with pharmaceutical companies, biotechnology firms, academic institutions, and other healthcare stakeholders in Europe and the United States.
Fiscal year 2025 · change from previous year
Development 2022–2025
Business
Share of revenueStandalone and integrated services for drug discovery, preclinical research, and development.
Just - Evotec Biologics capabilities for biologics design, process development, and manufacturing.
Long-term collaboration models with pharma, biotech, and research institutions.
Co-owned and partnered therapeutic programs and related intellectual property.
Customers
Evotec sells primarily to pharmaceutical companies, biotechnology firms, academic institutions, and other healthcare stakeholders that outsource research and development work or seek strategic collaboration. Its customer base uses Evotec for scientific capabilities, specialized platforms, and flexible partnership models that can range from discrete projects to multi-year programs. The business is designed to support customers across the drug development pipeline, from early discovery to biologics process development.
Buy discovery, preclinical, and biologics development services to augment internal R&D pipelines.
Use Evotec for specialized scientific platforms, development capacity, and partnership structures.
Engage Evotec for platform access, translational research support, and collaborative programs.
Use the company for outsourced drug discovery, disease modelling, and integrated R&D support.
Strategy
Evotec’s strategy centers on combining scientific platforms with AI-enabled discovery, advanced technologies, and flexible partnering structures. It also emphasizes biologics development and manufacturing through Just - Evotec Biologics, while maintaining a portfolio of proprietary and co-owned research assets that can create optionality over time.
Deeper partnerships improve customer stickiness and broaden project scope across the value chain.
Biologics capabilities widen the addressable market and add higher-complexity service offerings.
Platforms such as PanOmics and iPSC models strengthen differentiation and improve discovery productivity.
Geography
Evotec operates from sites in Europe and the United States, with scientific and operational work distributed across a global network of centres of excellence. The company’s footprint matters because discovery, development, and biologics capabilities are delivered close to major pharmaceutical and biotechnology clusters while also supporting cross-border partnering.
Risks
Evotec faces execution risk from complex, project-based drug discovery work, where revenue depends on winning and delivering scientific programs for external partners. The business is also exposed to funding and spending cycles in biotech, while its multinational footprint adds currency, credit, and operational complexity.
- Revenue timing and project execution riskImpact: HighLikelihood: High
The company depends on successful delivery of research programs and customer acceptance across multiple project stages.
Exposure: Discovery services and integrated R&D partnerships
- Biotech customer funding volatilityImpact: HighLikelihood: Medium
Many customers are biotechnology companies whose spending can slow when financing conditions tighten.
Exposure: Customer demand and project pipeline
- Asset impairment riskImpact: HighLikelihood: Medium
Specialized laboratory and property assets may need write-downs if capacity is underused or plans change.
Exposure: Laboratory sites and long-lived assets
- Foreign exchange riskImpact: MediumLikelihood: High
Operations and customers span Europe and the United States, creating exposure to multiple currencies.
Exposure: Cross-border operating costs and revenues
- Credit and liquidity riskImpact: MediumLikelihood: Medium
The company extends services to a wide set of counterparties and must fund working capital across programs.
Exposure: Receivables and contract execution
Accounting
Judgemental itemsScientific work may be recognized over time based on progress, milestones, and customer acceptance.
Impact: Affects revenue timing and comparability across periods
Specialized facilities can lose value if they are marketed for sublease or underutilized.
Impact: Can create significant non-cash charges
Minority stakes and venture holdings are subject to valuation changes and disposal gains or losses.
Impact: Can add volatility to other income and gains
Personnel and restoration obligations require estimates of severance, timing, and completion costs.
Impact: Affects operating expenses and liabilities
Similar listed companies
Publicly listed companies with a comparable business focus.
Oncotelic Therapeutics, Inc.
OTLC · Pharmaceutical Preparations
Evofem Biosciences, Inc.
EVFM · Pharmaceutical Preparations
Enveric Biosciences, Inc.
ENVB · Pharmaceutical Preparations
iBio, Inc.
IBIO · Pharmaceutical Preparations
Evommune, Inc.
EVMN · Pharmaceutical Preparations
Evogene Ltd.
EVGN · Agricultural Chemicals
Last updated: 28/09/2026